NO326689B1 - Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene - Google Patents
Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelseneInfo
- Publication number
- NO326689B1 NO326689B1 NO20035440A NO20035440A NO326689B1 NO 326689 B1 NO326689 B1 NO 326689B1 NO 20035440 A NO20035440 A NO 20035440A NO 20035440 A NO20035440 A NO 20035440A NO 326689 B1 NO326689 B1 NO 326689B1
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- preparation
- pharmaceutical composition
- pyrrolidine derivatives
- pyrrolidine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003235 pyrrolidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0114005.2A GB0114005D0 (en) | 2001-06-08 | 2001-06-08 | Chemical compounds |
| PCT/GB2002/002721 WO2002100830A1 (en) | 2001-06-08 | 2002-06-06 | Pyrrolidine derivatives as factor xa inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20035440D0 NO20035440D0 (no) | 2003-12-05 |
| NO326689B1 true NO326689B1 (no) | 2009-01-26 |
Family
ID=9916209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20035440A NO326689B1 (no) | 2001-06-08 | 2003-12-05 | Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US7186717B2 (no) |
| EP (1) | EP1395553B1 (no) |
| JP (1) | JP4242274B2 (no) |
| KR (1) | KR100877245B1 (no) |
| CN (1) | CN1256324C (no) |
| AR (1) | AR036086A1 (no) |
| AT (1) | ATE289294T1 (no) |
| AU (1) | AU2002311451B2 (no) |
| BR (1) | BR0210207A (no) |
| CA (1) | CA2449629A1 (no) |
| CO (1) | CO5540285A2 (no) |
| CZ (1) | CZ20033325A3 (no) |
| DE (1) | DE60203006T2 (no) |
| DK (1) | DK1395553T3 (no) |
| ES (1) | ES2235050T3 (no) |
| GB (1) | GB0114005D0 (no) |
| HU (1) | HUP0400156A3 (no) |
| IL (1) | IL159195A0 (no) |
| MX (1) | MXPA03011384A (no) |
| MY (1) | MY136859A (no) |
| NO (1) | NO326689B1 (no) |
| NZ (1) | NZ530004A (no) |
| PL (1) | PL368082A1 (no) |
| PT (1) | PT1395553E (no) |
| SI (1) | SI1395553T1 (no) |
| TW (1) | TWI298719B (no) |
| WO (1) | WO2002100830A1 (no) |
| ZA (1) | ZA200309367B (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0130705D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
| US20050119266A1 (en) * | 2003-10-01 | 2005-06-02 | Yan Shi | Pyrrolidine and piperidine derivatives as factor Xa inhibitors |
| PL1637141T3 (pl) * | 2004-09-21 | 2012-04-30 | Trobio Ab | Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej |
| WO2006047415A2 (en) * | 2004-10-26 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Factor xa compounds |
| WO2006110726A2 (en) * | 2005-04-11 | 2006-10-19 | Glaxo Group Limited | Dosage formulations and methods of treatment and prevention |
| CN102380100A (zh) * | 2005-09-22 | 2012-03-21 | 特罗比奥股份公司 | 稳定的蛋白酶组合物 |
| JP5080476B2 (ja) * | 2005-09-22 | 2012-11-21 | トルービオ・アーベー | 安定化プロテアーゼ組成物 |
| DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
| SI2989095T1 (sl) * | 2013-04-26 | 2019-03-29 | Sanofi | Tartratna sol 5-kloro-tiopen-2-karboksilne kisline((s)-2-(metil-3-(2-okso-pirolidin-1-il)-benzensulfonilamino)-3- (4-metil piperazin-1 il)-3-okso-propril)amida |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| EP3078378B1 (en) | 2015-04-08 | 2020-06-24 | Vaiomer | Use of factor xa inhibitors for regulating glycemia |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92011A0 (en) | 1988-10-19 | 1990-07-12 | Abbott Lab | Heterocyclic peptide renin inhibitors |
| DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE4121947A1 (de) * | 1991-07-03 | 1993-01-07 | Basf Ag | 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung |
| US5703208A (en) | 1994-06-17 | 1997-12-30 | Corvas International, Inc. | 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors |
| CA2268281A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| DK0944386T3 (da) | 1996-12-13 | 2003-01-27 | Aventis Pharma Inc | Sulfonsyre- eller sulfonylamino-N-(heteroaralkyl)-azaheterocyclylamid-forbindelser |
| US6602864B1 (en) | 1996-12-13 | 2003-08-05 | Aventis Pharma Deutschland Gmbh | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds |
| US6281227B1 (en) | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| IL123986A (en) | 1997-04-24 | 2011-10-31 | Organon Nv | Medicinal compounds |
| KR20010015639A (ko) | 1997-09-30 | 2001-02-26 | 스즈키 다다시 | 술포닐 유도체 |
| WO1999037304A1 (en) | 1998-01-27 | 1999-07-29 | Aventis Pharmaceuticals Products Inc. | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS |
| AU3535199A (en) | 1998-04-22 | 1999-11-08 | Showa Denko Kabushiki Kaisha | Particulate metal oxide with evenly fluorinated surface, process for producing the same, and use |
| EP1150976B1 (en) | 1998-12-31 | 2003-02-26 | Aventis Pharmaceuticals Inc. | 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| JP2002536437A (ja) | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | FXaのラクタム抑制剤および方法 |
| AU3192500A (en) * | 1999-03-16 | 2000-10-04 | C & C Research Laboratories | Substituted proline derivatives and medicinal compositions containing the same |
| WO2000069465A1 (en) | 1999-05-12 | 2000-11-23 | Ono Pharmaceutical Co., Ltd. | Anticancer agents containing ep1 antagonists as the active ingredient |
| CZ2002323A3 (cs) | 1999-07-28 | 2002-05-15 | Aventis Pharmaceuticals Products Inc. | Substituované oxoazaheterocyklylové sloučeniny a farmaceutické prostředky, které je obsahují |
| JP2004518688A (ja) | 2001-01-30 | 2004-06-24 | ブリストル−マイヤーズ スクイブ カンパニー | ファクターXa阻害剤のスルホンアミドラクタムおよびその方法 |
| GB0114005D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0114004D0 (en) * | 2001-06-08 | 2001-08-01 | Glaxo Group Ltd | Chemical compounds |
| GB0228533D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Crystalline form |
| GB0228552D0 (en) * | 2002-12-06 | 2003-01-15 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-06-08 GB GBGB0114005.2A patent/GB0114005D0/en not_active Ceased
-
2002
- 2002-06-06 MX MXPA03011384A patent/MXPA03011384A/es active IP Right Grant
- 2002-06-06 MY MYPI20022097A patent/MY136859A/en unknown
- 2002-06-06 PL PL02368082A patent/PL368082A1/xx unknown
- 2002-06-06 TW TW091112153A patent/TWI298719B/zh active
- 2002-06-06 AU AU2002311451A patent/AU2002311451B2/en not_active Ceased
- 2002-06-06 PT PT02738368T patent/PT1395553E/pt unknown
- 2002-06-06 NZ NZ530004A patent/NZ530004A/en unknown
- 2002-06-06 CA CA002449629A patent/CA2449629A1/en not_active Abandoned
- 2002-06-06 AT AT02738368T patent/ATE289294T1/de not_active IP Right Cessation
- 2002-06-06 ES ES02738368T patent/ES2235050T3/es not_active Expired - Lifetime
- 2002-06-06 IL IL15919502A patent/IL159195A0/xx unknown
- 2002-06-06 SI SI200230101T patent/SI1395553T1/xx unknown
- 2002-06-06 HU HU0400156A patent/HUP0400156A3/hu unknown
- 2002-06-06 CZ CZ20033325A patent/CZ20033325A3/cs unknown
- 2002-06-06 US US10/479,545 patent/US7186717B2/en not_active Expired - Fee Related
- 2002-06-06 DE DE60203006T patent/DE60203006T2/de not_active Expired - Lifetime
- 2002-06-06 JP JP2003503599A patent/JP4242274B2/ja not_active Expired - Fee Related
- 2002-06-06 BR BR0210207-2A patent/BR0210207A/pt not_active Application Discontinuation
- 2002-06-06 CN CNB028154002A patent/CN1256324C/zh not_active Expired - Fee Related
- 2002-06-06 AR ARP020102128A patent/AR036086A1/es unknown
- 2002-06-06 WO PCT/GB2002/002721 patent/WO2002100830A1/en not_active Ceased
- 2002-06-06 DK DK02738368T patent/DK1395553T3/da active
- 2002-06-06 EP EP02738368A patent/EP1395553B1/en not_active Expired - Lifetime
- 2002-06-06 KR KR1020037016070A patent/KR100877245B1/ko not_active Expired - Fee Related
-
2003
- 2003-12-02 ZA ZA200309367A patent/ZA200309367B/en unknown
- 2003-12-05 NO NO20035440A patent/NO326689B1/no not_active IP Right Cessation
- 2003-12-05 CO CO03107408A patent/CO5540285A2/es not_active Application Discontinuation
-
2006
- 2006-10-11 US US11/548,395 patent/US7429587B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,402 patent/US7517879B2/en not_active Expired - Fee Related
- 2006-10-11 US US11/548,404 patent/US7326785B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329884B1 (no) | Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten | |
| NO2014009I2 (no) | Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser | |
| EE200200487A (et) | Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon | |
| EE200100684A (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
| LTPA2014005I1 (lt) | Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas | |
| EE200100431A (et) | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine | |
| NO324227B1 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer | |
| PL375790A1 (en) | Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof | |
| EE200300370A (et) | Atsüülitud 6,7,8,9-tetrahüdro-5H-bensotsükloheptenüülamiinid, nende valmistamismeetod, kasutamine ja farmatseutiline preparaat | |
| AU2003246810A1 (en) | Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives | |
| NO326689B1 (no) | Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene | |
| EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
| NO20041879D0 (no) | Polymorf form av rimonabant, fremgangsmate for fremstilling derav og farmasoytisk preparat inneholdende det samme. | |
| NO20016038L (no) | Benzenderivater, fremgangsmåte for deres fremstilling og farmasöytiske preparater inneholdende de samme | |
| NO20030012L (no) | Fremgangsmåte for fremstilling av substituerte oktanoylamider | |
| EE200300327A (et) | Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon | |
| HUP0401747A3 (en) | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds | |
| NO20034864D0 (no) | Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner | |
| PL347105A1 (en) | Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof | |
| DE60301570D1 (de) | 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| EE200100422A (et) | Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine | |
| EE04346B1 (et) | Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon | |
| NO20042640L (no) | Fremgangsmate for fremstilling av ekinocandinderivater | |
| DK1118610T3 (da) | Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne | |
| NO20035586D0 (no) | Fremgangsmåte for fremstilling av cykloheksanol-derivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |